30.17

0.13% 0.04

Kymera Therapeutics Inc (KYMR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$30.13

Offen:

$29.89

24-Stunden-Volumen:

386.40K

Relative Volume:

0.54

Marktkapitalisierung:

$1.96B

Einnahmen:

$87.56M

Nettoeinkommen (Verlust:

$-167.47M

KGV:

-12.89

EPS:

-2.34

Netto-Cashflow:

$-148.20M

1W Leistung:

+0.50%

1M Leistung:

+4.76%

6M Leistung:

-32.93%

1J Leistung:

-15.49%

1-Tages-Spanne:

$29.84

$30.78

1-Wochen-Bereich:

$29.15

$31.47

52-Wochen-Spanne:

$19.45

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Firmenname

Kymera Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (668)

Telefon

857-285-5314

Adresse

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Mitarbeiter

208

Twitter

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

KYMR's Discussions on Twitter

Vergleichen Sie KYMR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KYMR Kymera Therapeutics Inc	30.17	1.95B	87.56M	-167.47M	-148.20M	-2.34
ONC Beigene Ltd Adr	238.76	24.41B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	434.03	111.55B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.2548	42.47M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	596.85	63.16B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	72.69	5.92B	0	-153.72M	-103.81M	-2.00

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-13	Eingeleitet	Citigroup	Buy
2024-12-10	Eingeleitet	BTIG Research	Buy
2024-12-06	Eingeleitet	BMO Capital Markets	Market Perform
2024-12-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-11-18	Eingeleitet	Stephens	Overweight
2024-09-09	Fortgesetzt	Leerink Partners	Outperform
2024-08-26	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-04-22	Eingeleitet	Oppenheimer	Outperform
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2024-01-04	Hochstufung	JP Morgan	Neutral → Overweight
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-12-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-06-30	Eingeleitet	Truist	Buy
2023-05-05	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-12-06	Herabstufung	Credit Suisse	Outperform → Neutral
2022-11-08	Eingeleitet	Raymond James	Mkt Perform
2022-08-15	Eingeleitet	Jefferies	Buy
2022-08-03	Eingeleitet	Goldman	Buy
2022-07-20	Eingeleitet	SVB Leerink	Mkt Perform
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-03-10	Eingeleitet	JP Morgan	Neutral
2022-02-10	Eingeleitet	Wells Fargo	Overweight
2021-09-30	Eingeleitet	B. Riley Securities	Neutral
2021-09-30	Eingeleitet	Stifel	Buy
2021-09-10	Herabstufung	BofA Securities	Buy → Neutral
2021-05-21	Eingeleitet	UBS	Buy
2021-04-14	Eingeleitet	Berenberg	Buy
2020-12-04	Eingeleitet	H.C. Wainwright	Buy
2020-09-15	Eingeleitet	BofA Securities	Neutral
2020-09-15	Eingeleitet	Cowen	Outperform
2020-09-15	Eingeleitet	Guggenheim	Buy
2020-09-15	Eingeleitet	Morgan Stanley	Equal-Weight

Alle ansehen

Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten

May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025

May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus

May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com

May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria

May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus

May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025

May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025

May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025

May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025